Literature DB >> 17591957

Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically.

Abdiaziz S Mohamood1, Mehmet L Guler, Zuoxiang Xiao, Dongfeng Zheng, Allan Hess, Yi Wang, Hideo Yagita, Jonathan P Schneck, Abdel Rahim A Hamad.   

Abstract

Spontaneous mutation of Fas (lpr) or FasL (gld) completely protects nonobese diabetic mice from autoimmune diabetes but also causes massive double-negative T-cell lymphoproliferation. In this study, we used bone marrow chimeras and adoptive transfer analysis to investigate further the role of FasL in the pathogenesis of autoimmune diabetes and to determine whether gld-induced tolerance and double-negative T-cell lymphoproliferation can be uncoupled from each other. We show that FasL expressed on hematopoietic and nonhematopoietic compartments plays nonredundant roles in the pathogenesis of autoimmune diabetes. Mutation of FasL in either compartment interferes with the autoimmune process and prevents onset of diabetes, but FasL expressed in the hematopoietic compartment is the dominant regulator of T-cell homeostasis. Furthermore, pathogenesis of diabetes is dependent on normal FasL expression in both compartments, whereas only minimal FasL function is required to maintain T-cell homeostasis. Consequently, partial disruption of FasL protects from autoimmune diabetes without causing T-cell lymphoproliferation. This is demonstrated genetically in nonobese diabetic-gld/+ mice and pharmacologically by using FasL-neutralizing antibody. These results have important implications for understanding the role of the Fas pathway in pathogenesis of autoimmune diseases and for designing novel FasL-modulating therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591957      PMCID: PMC1941609          DOI: 10.2353/ajpath.2007.070148

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  41 in total

1.  Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells.

Authors:  F J Schaub; D K Han; W C Liles; L D Adams; S A Coats; R K Ramachandran; R A Seifert; S M Schwartz; D F Bowen-Pope
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

2.  A metalloproteinase inhibitor prevents lethal acute graft-versus-host disease in mice.

Authors:  K Hattori; T Hirano; C Ushiyama; H Miyajima; N Yamakawa; T Ebata; Y Wada; S Ikeda; K Yoshino; M Tateno; K Oshimi; N Kayagaki; H Yagita; K Okumura
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

Review 3.  Regulatory T cells in autoimmmunity*.

Authors:  E M Shevach
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

4.  Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved.

Authors:  S Kim; K A Kim; D Y Hwang; T H Lee; N Kayagaki; H Yagita; M S Lee
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

5.  Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system.

Authors:  K A Sabelko; K A Kelly; M H Nahm; A H Cross; J H Russell
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

6.  Polymorphism of murine Fas ligand that affects the biological activity.

Authors:  N Kayagaki; N Yamaguchi; F Nagao; S Matsuo; H Maeda; K Okumura; H Yagita
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

7.  Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway.

Authors:  D Ashany; A Savir; N Bhardwaj; K B Elkon
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

8.  Significant role for Fas in the pathogenesis of autoimmune diabetes.

Authors:  X Su; Q Hu; J M Kristan; C Costa; Y Shen; D Gero; L A Matis; Y Wang
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

9.  Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice.

Authors:  N Itoh; A Imagawa; T Hanafusa; M Waguri; K Yamamoto; H Iwahashi; M Moriwaki; H Nakajima; J Miyagawa; M Namba; S Makino; S Nagata; N Kono; Y Matsuzawa
Journal:  J Exp Med       Date:  1997-08-18       Impact factor: 14.307

10.  Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival.

Authors:  A M Hohlbaum; S Moe; A Marshak-Rothstein
Journal:  J Exp Med       Date:  2000-04-03       Impact factor: 14.307

View more
  12 in total

1.  T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy.

Authors:  Tori N Yamamoto; Ping-Hsien Lee; Suman K Vodnala; Devikala Gurusamy; Rigel J Kishton; Zhiya Yu; Arash Eidizadeh; Robert Eil; Jessica Fioravanti; Luca Gattinoni; James N Kochenderfer; Terry J Fry; Bulent Arman Aksoy; Jeffrey E Hammerbacher; Anthony C Cruz; Richard M Siegel; Nicholas P Restifo; Christopher A Klebanoff
Journal:  J Clin Invest       Date:  2019-02-25       Impact factor: 14.808

2.  Inhibition of Fas ligand in NOD mice unmasks a protective role for IL-10 against insulitis development.

Authors:  Zuoxiang Xiao; Abdiaziz S Mohamood; Sophia Uddin; Rachel Gutfreund; Chiaki Nakata; Andrew Marshall; Hiroaki Kimura; Patrizio Caturegli; Karl L Womer; Yanfei Huang; Chunfa Jie; Shukti Chakravarti; Jonathan P Schneck; Hideo Yagita; Abdel Rahim A Hamad
Journal:  Am J Pathol       Date:  2011-06-15       Impact factor: 4.307

Review 3.  Double negative (DN) αβ T cells: misperception and overdue recognition.

Authors:  Maria N Martina; Sanjeev Noel; Ankit Saxena; Hamid Rabb; Abdel Rahim A Hamad
Journal:  Immunol Cell Biol       Date:  2014-11-25       Impact factor: 5.126

4.  Blocking Fas ligand on leukocytes attenuates kidney ischemia-reperfusion injury.

Authors:  Gang Jee Ko; Hye Ryoun Jang; Yanfei Huang; Karl L Womer; Manchang Liu; Elizabeth Higbee; Zuoxiang Xiao; Hideo Yagita; Lorraine Racusen; Abdel Rahim A Hamad; Hamid Rabb
Journal:  J Am Soc Nephrol       Date:  2011-03-24       Impact factor: 10.121

5.  From non-obese diabetic to Network for the Pancreatic Organ Donor with Diabetes: New heights in type 1 diabetes research.

Authors:  Lourdes Ramirez; Abdel Rahim A Hamad
Journal:  World J Diabetes       Date:  2015-11-25

6.  Status of autoimmune diabetes 20-year after generation of BDC2.5-TCR transgenic non-obese diabetic mouse.

Authors:  Lourdes Ramirez; Abdel Rahim A Hamad
Journal:  World J Diabetes       Date:  2013-08-15

Review 7.  Analysis of gene profile, steady state proliferation and apoptosis of double-negative T cells in the periphery and gut epithelium provides new insights into the biological functions of the Fas pathway.

Authors:  Abdel Rahim A Hamad
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

Review 8.  B cell-targeted immunotherapy for type 1 diabetes: What can make it work?

Authors:  Abdel Rahim A Hamad; Rizwan Ahmed; Thomas Donner; Georgia Fousteri
Journal:  Discov Med       Date:  2016-03       Impact factor: 2.970

9.  The potential of Fas ligand (apoptosis-inducing molecule) as an unconventional therapeutic target in type 1 diabetes.

Authors:  Abdel Rahim A R Hamad; Kristin Arcara; Sophia Uddin; Thomas Donner
Journal:  Front Immunol       Date:  2012-07-12       Impact factor: 7.561

10.  Fas-mediated apoptosis regulates the composition of peripheral alphabeta T cell repertoire by constitutively purging out double negative T cells.

Authors:  Abdiaziz S Mohamood; Dylan Bargatze; Zuoxiang Xiao; Chunfa Jie; Hideo Yagita; Dawn Ruben; Julie Watson; Shukti Chakravarti; Jonathan P Schneck; Abdel Rahim A Hamad
Journal:  PLoS One       Date:  2008-10-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.